^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    varegacestat (AL102)

    i
    Other names: AL102, AL-102, AL 102, BMS-986115
    Associations

    News

    Trials
    Company:
    Immunome
    Drug class:
    γ-secretase inhibitor, Notch inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Varegacestat Hepatic Impairment Study (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, Immunome, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    varegacestat (AL102)
    2ms
    A Phase 1 Mass Balance Study of Varegacestat (clinicaltrials.gov)
    P1, N=6, Completed, Immunome, Inc. | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Mar 2025 | Trial primary completion date: Jul 2025 --> Mar 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    varegacestat (AL102)
    2ms
    A Cardiac Liability Study of Varegacestat in Healthy Participants (clinicaltrials.gov)
    P1, N=32, Completed, Immunome, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    varegacestat (AL102)
    3ms
    Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors. (PubMed, Future Oncol)
    GS enzyme inhibitors such as semagacestat and avagacestat were explored in AD but the studies were paused because of adverse events attributed to their influence on the Notch pathway.Crosstalk between Notch and Wnt signaling pathways created a potential role for GS inhibitors in the treatment of malignancies such as glioblastoma multiforme, pancreatic, and breast cancers. Emphasis was placed on patient-reported outcomes (PRO) including the DT-specific tool, GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom Scale (GODDESS).Nirogacestat received Food and Drug Administration (FDA) approval in November 2023 for management of progressive, unresectable, recurrent, or refractory DT. Further studies are underway to investigate other GS inhibitors such as AL-102 in the management of DT.
    Review • Journal
    |
    APP (Amyloid Beta Precursor Protein)
    |
    Ogsiveo (nirogacestat) • varegacestat (AL102)
    7ms
    A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants (clinicaltrials.gov)
    P1, N=22, Completed, Immunome, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    itraconazole • varegacestat (AL102)
    8ms
    A Cardiac Liability Study of Varegacestat in Healthy Participants (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Immunome, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    varegacestat (AL102)
    8ms
    A Phase 1 Mass Balance Study of Varegacestat (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Immunome, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    varegacestat (AL102)
    9ms
    A Varegacestat Hepatic Impairment Study (clinicaltrials.gov)
    P1, N=44, Recruiting, Immunome, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    varegacestat (AL102)
    9ms
    A Cardiac Liability Study of Varegacestat in Healthy Participants (clinicaltrials.gov)
    P1, N=32, Recruiting, Immunome, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    varegacestat (AL102)
    9ms
    A Cardiac Liability Study of Varegacestat in Healthy Participants (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Immunome, Inc.
    New P1 trial
    |
    varegacestat (AL102)
    9ms
    A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Immunome, Inc. | Trial completion date: Jan 2025 --> Apr 2025
    Trial completion date
    |
    itraconazole • varegacestat (AL102)
    9ms
    A Phase 1 Mass Balance Study of Varegacestat (clinicaltrials.gov)
    P1, N=6, Recruiting, Immunome, Inc.
    New P1 trial
    |
    varegacestat (AL102)